当社グループは 3,000 以上の世界的なカンファレンスシリーズ 米国、ヨーロッパ、世界中で毎年イベントが開催されます。 1,000 のより科学的な学会からの支援を受けたアジア および 700 以上の オープン アクセスを発行ジャーナルには 50,000 人以上の著名人が掲載されており、科学者が編集委員として名高い
。オープンアクセスジャーナルはより多くの読者と引用を獲得
700 ジャーナル と 15,000,000 人の読者 各ジャーナルは 25,000 人以上の読者を獲得
Le Ngoc Hung, Nguyen Huu Tung, Cao Hung Phu, Nguyen Van Bac, Nguyen Manh Hoa
When the worldwide population enters the period of vaccination against SARS-CoV-2 infection, the more information on immune response, the better for the prevention strategy against COVID-19. We reported herein the results of SARS-CoV-2 antibodies in a cross-sectional study 75 Vietnamese participants divided into 3 groups: Auninfected person with 2 doses vaccination (“Vac” group; n=32); B: convalescent person who received first dose vaccine then having COVID-19 infection (“Vac-F0” group; n=12); and C: unvaccinated convalescent person with previous COVID-19 infection (“F0” group; n=31). The “F0” group had 26% (8/31) with antibodies higher than 250 U/mL, significantly lower than those from “Vac” group (84.4%, 27/32) and “Vac-F0” group (83.3%, 10/12), p=0.000. There were 3 cases in “F0” group with “no immune response” (<0.4 U/mL, 9.7%). No difference in antibodies between “Vac” and “Vac-F0” group. Among “F0” group, “non-severe infection” person had immune response lower than that from whom with severe infection (p=0.04). Unvaccinated convalescent person with previous infection had low immunity against SARS-CoV-2 virus. The antibody measurement is essential to identify this at-risk population and an additional dose of vaccine is needed for them.